Lab-on-Skin Microfluidic Patch Global Market Report 2025

The lab-on-skin microfluidic patch market size has grown exponentially in recent years. It will grow from $1.2 billion in 2024 to $1.44 billion in 2025 at a compound annual growth rate (CAGR) of 20.3%. Growth during the historic period can be attributed to the rising prevalence of chronic and lifestyle-related diseases, increasing demand for non-invasive diagnostic solutions, growing awareness of continuous health monitoring, the surge in personalized healthcare approaches, expansion of home-based healthcare services, and the increasing emphasis on preventive health management.

The lab-on-skin microfluidic patch market size is expected to see rapid growth in the next few years. It will grow to $2.98 billion in 2029 at a compound annual growth rate (CAGR) of 20%. Growth during the forecast period can be attributed to the rising adoption of wearable health monitoring devices, increasing healthcare spending in developing regions, growing emphasis on remote patient monitoring, surge in government efforts to promote digital health, expansion of healthcare infrastructure in emerging economies, and growing consumer demand for real-time health insights. Key trends expected in this period include technological progress in biosensing materials and microfluidic integration, improvements in flexible and biocompatible substrates, innovations in wireless data transmission and connectivity, advancements in sweat and interstitial fluid analysis methods, ongoing research and development in multi-analyte detection platforms, and the emergence of energy-efficient and self-powered patch systems.

The growing focus on personalized medicine is anticipated to drive the expansion of the lab-on-skin microfluidic patch market in the coming years. Personalized medicine is a healthcare approach that tailors medical treatment and preventive strategies to an individual’s genetic, biomarker, and clinical profile to achieve better therapeutic outcomes. The increasing adoption of personalized medicine is supported by advances in genomics and biotechnology, which enable accurate diagnoses and targeted therapies that enhance treatment effectiveness and reduce unnecessary interventions. Lab-on-skin microfluidic patches contribute to this approach by continuously monitoring unique biomarkers, allowing real-time, individualized treatment decisions. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization promoting personalized medicine, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, compared to six approvals in 2022. Therefore, the rising emphasis on personalized medicine is propelling the growth of the lab-on-skin microfluidic patch market.

Companies operating in the lab-on-skin microfluidic patch market are increasingly developing advanced microfluidic technologies, such as sweat-sensing patches, to support real-time health monitoring and personalized diagnostics. A sweat-sensing patch is a wearable device that collects and analyzes sweat to track biomarkers, electrolytes, and other physiological indicators continuously. For example, in April 2024, Epicore Biosystems Inc., a US-based digital health company, launched Connected Hydration, a wearable microfluidic patch paired with a mobile application that helps industrial workers prevent dehydration and heat stress through continuous sweat and electrolyte monitoring. It offers real-time personalized hydration insights, vibration alerts, and AI-based recommendations to optimize fluid intake before fatigue or injury occurs. By integrating lab-on-skin sensing, cloud-based analytics, and a long-lasting battery system, Connected Hydration improves worker safety, productivity, and endurance in extreme heat environments across global industrial sectors.

In February 2024, Epicore Biosystems Inc. entered into a partnership with the US Anti-Doping Agency (USADA) to advance its microfluidic sweat patch technology for doping detection. This collaboration aims to enable non-invasive sweat biomarker collection for drug testing, improving the efficiency and convenience of anti-doping procedures while providing athletes with real-time health insights. The US Anti-Doping Agency is a US-based nonprofit and non-governmental organization responsible for implementing a comprehensive anti-doping program for ParaPan American sports in the United States.

Major players in the lab-on-skin microfluidic patch market are Abbott Laboratories, Medtronic plc, GE HealthCare Technologies Inc., Persperity Health Inc., Biolinq Inc., VivaLNK Inc., Blue Spark Technologies Inc., GraphWear Technologies Inc., Nutromics Pty Ltd., Aline Inc., Caliber Imaging & Diagnostics Inc., Flow Bio Ltd., GENTAG Inc., Nemaura Medical Inc., Zansors LLC, Epicore Biosystems Inc., Kenzen Inc., Xsensio SA, Rhaeos Inc., and PointFit Technology Co. Ltd.

North America was the largest region in the lab-on-skin microfluidic patch market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lab-on-skin microfluidic patch report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The lab-on-skin microfluidic patch market research report is one of a series of new reports that provides lab-on-skin microfluidic patch market statistics, including lab-on-skin microfluidic patch industry global market size, regional shares, competitors with a lab-on-skin microfluidic patch market share, detailed lab-on-skin microfluidic patch market segments, market trends and opportunities, and any further data you may need to thrive in the lab-on-skin microfluidic patch industry. This lab-on-skin microfluidic patch market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A lab-on-skin microfluidic patch is a wearable device that combines microfluidic technology with a flexible, skin-adhering surface to continuously collect and analyze biofluids such as sweat, interstitial fluid, or tears. It operates as a compact laboratory on the skin, allowing real-time monitoring of physiological indicators such as electrolytes, glucose, lactate, and hydration levels for applications in health diagnostics, athletic performance, and personalized medicine.

The primary product types of lab-on-skin microfluidic patches include diagnostic patches, therapeutic patches, monitoring patches, and others. Diagnostic patches are skin-worn devices designed to detect and identify biomarkers such as ions, metabolites, or proteins that reflect disease states or physiological conditions. These patches are composed of materials such as polymer-based, paper-based, hybrid, and others. They are used in healthcare monitoring, disease diagnosis, drug delivery, sports and fitness, and other applications, serving end-users such as hospitals and clinics, homecare, research institutes, sports and fitness centers, and others.

The countries covered in the lab-on-skin microfluidic patch market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lab-on-skin microfluidic patch market consists of sales of sensors, microfluidic chips, flexible substrates, electrodes, biosensors, hydrogels, and wearable bands. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.